Seagen's TUKYSA Wins European Approval For Metastatic Breast Cancer

by Vandana Singh, Benzinga Editor

February 12, 2021 8:16 AM | 1 min read | Make a Comment

The European Commission (EC) has granted marketing authorization to Seagen Inc's (NASDAQ: SGEN) TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, to treat adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
TUKYSA is an oral, small-molecule tyrosine kinase inhibitor of HER2, a protein that contributes to cancer cell growth.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for TUKYSA in December last year.
Price Action: SGEN stock slips 0.07% at $171.9 in premarket trading hours on the last check Friday.

Posted In: Biotech News Health Care FDA General breast cancer European Commission

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.